Table 1 Study characteristics of SP-IPTi efficacy trials
Study parameter | Schellenberg et al. [2, 3] | Chandramohan et al. [4] | Macete et al[5] | Kobbe et al. [6] | Mockenhaupt et al. [7] | Grobusch et al[8] |
|---|---|---|---|---|---|---|
Trial, country | Ifakara, Tanzania | Navrongo, Ghana | Manhica, Mozambique | Kumasi, Ghana | Tamale, Ghana | Lambaréné, Gabon |
Recruitment year(s) | 1999–2000 | 2000–2002 | 2002–2004 | 2003–2005 | 2003 | 2004–2005 |
EIR/year | 29 | 418 | 38 | 400 | NA | 50 |
Transmission | Perennial moderate | Highly seasonal high | Perennial with seasonal peaks moderate | Perennial high | Perennial with seasonal peaks high | Perennial with seasonal peaks low-moderate |
In vivo SP resistance by day 14% | 31 (1999–2000) [10] | 22 (2004) [11] | 21 (2001) [12] | NA | 14 (2002) [14] | 21 (2004) [13] |
Use of bed nets, % placebo/SP treated (untreated) | 67/68 | 17/19 | 0/0 (14/15) | 20/20 estimate (39/38) | <1% | 5/5 (80/80) |
Iron supplementation | Yes | Yes | None | None | None | None |
Ages at dosing, months | 2, 3, 9 (at time of DPT2, DPT3 & measles) | 3, 4, 9, 12 (at time of DPT2, DPT3 & measles + extra at 12 months) | 3, 4, 9 (at time of DPT2, DPT3 & measles) | 3, 9, 15 (at time of DPT3 & measles + extra at 15 months) | 3, 9, 15 (at time of DPT3 & measles + extra at 15 months) | 3, 9, 15 (at time of DPT3 & measles + extra at 15 months) |
No. of children enrolled, placebo/active | 351/350 = 701 | 1,242/1,243 = 2,485 | 755/748 = 1,503 | 535/535 = 1,070 | 600/600 = 1,200 | 595/594 = 1,189 |
Study design | Individual randomization | Cluster randomization | Individual randomization | Individual randomization | Individual randomization | Individual randomization |